Safety and Efficiency of γδ T Cell Against Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT03183232
- Lead Sponsor
- Fuda Cancer Hospital, Guangzhou
- Brief Summary
In this study, effects of γδT cells on human Lung Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated
- Detailed Description
Lung tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.
NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks.
Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Age: 18-75 Karnofsky performance status >50 Diagnosis with Lung Cancer based on histology or the current accepted radiological measures Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, IRE, gd T cells Life expectancy: Greater than 3 months Ability to understand the study protocol and a willingness to sign a written informed consent document
Patients with other kinds of cancer History of coagulation disorders or anemia Patients with heart disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Relief degree of tumors 3 months It will be evaluated by the Response Evaluation Criteria in Solid Tumors
Progress free survival（PFS) 1 year Overall survival（OS） 3 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Biotherapy center in Fuda cancer hospital
🇨🇳Guangzhou, Guangdong, China
Biotherapy center in Fuda cancer hospital🇨🇳Guangzhou, Guangdong, China